Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewTrichostatin A is a selective and potent inhibitor of class I and II histone deacetylases (HDAC) (Ki = 3.4 nM, IC50 values are 4.99 nM, 5.21 nM, 16.4 nM, 24.3 nM, 27.6 nM for HDAC1, 3, 6, 10 and 4, respectively). Trichostatin A induces accelerated dedifferentiation of primordial germ cells (PGCs) into embryonic germ (EG) cells. Trichostatin A potently inhibits a range of breast cancer and melanoma cell lines (IC50 = 29-400 nM) and induces apoptosis in prostate cancer cells. In an animal model of Huntington's disease, inhibition of HDAC by Trichostatin A rescues memory deficits and increases expression of CREB/CBP target genes in mutant mice. Activates autophagy, increases vesicular transport of BDNF (Cat. No. 2837) and is active in vivo.Trichostatin A enhances CRISPR-Cas9 gene editing of human induced pluripotent stem cells (iPSCs).
M. Wt | 302.37 |
Formula | C17H22N2O3 |
Storage | Store at -20°C |
Purity | ≥95% (HPLC) |
CAS Number | 58880-19-6 |
PubChem ID | 444732 |
InChI Key | RTKIYFITIVXBLE-QEQCGCAPSA-N |
Smiles | O=C([C@H](C)/C=C(C)/C=C/C(NO)=O)C1=CC=C(N(C)C)C=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 5 | 17 |
The following data is based on the product molecular weight 302.37. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.17 mM | 19.45 mL | 97.27 mL | 194.54 mL |
0.85 mM | 3.89 mL | 19.45 mL | 38.91 mL |
1.7 mM | 1.95 mL | 9.73 mL | 19.45 mL |
8.5 mM | 0.39 mL | 1.95 mL | 3.89 mL |
References are publications that support the biological activity of the product.
Durcova-Hills et al (2008) Reprogramming primordial germ cells into pluripotent stem cells. PloS ONE 3 e3531 PMID: 18953407
Yoshida et al (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J.Biol.Chem. 265 17174 PMID: 2211619
Vigushin et al (2001) Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin.Cancer Res. 7 971 PMID: 11309348
Wharton et al (2000) Inhibition of mitogenesis in Balb/c-3T3 cells by trichostatin A. J.Biol.Chem. 275 33981 PMID: 10945992
Galluzzi et al (2017) Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nat.Rev.Drug.Discov. PMID: 28529316
Tatamiya et al (2004) Isozyme-selective activity of the HDAC inhibitor MS-275. Proc.Amer.Assoc.Cancer Res. 45
Giralt et al (2012) Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity. Hum.Mol.Genet. 21 1203 PMID: 22116937
Molugu et al (2023) Trichostatin A for efficient CRISPR-Cas9 gene editing of human pluripotent stem cells. CRISPR J. 6 473 PMID: 37676985
If you know of a relevant reference for Trichostatin A, please let us know.
Keywords: Trichostatin A, Trichostatin A supplier, Histone, deacetylase, inhibitors, inhibits, HDAC, Deacetylases, TrichostatinA, stem, cells, epigenetics, cancer, melanoma, apoptosis, Huntingtons, autophagy, BDNF, CRISPR, Cas9, reagents, iPSCs, Stem, Cell, Reprogramming, Autophagy, Non-selective, HDACs, Non-Selective, Reagents, 1406, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for Trichostatin A include:
Parira et al (2019) Trichostatin A Shows Transient Protection from Chronic Alcohol-Induced Reactive Oxygen Species (ROS) Production in Human Monocyte-Derived Dendritic Cells. J Alcohol Drug Depend 6 PMID: 30596124
Xia et al (2013) Identification of repurposed small molecule drugs for chordoma therapy. Cancer Biol Ther 14 638 PMID: 23792643
Kurita et al (2012) HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci 15 1245 PMID: 22864611
Lu et al (2019) Histone deacetylase 4 promotes type I IF. signaling, restricts DNA viruses, and is degraded via vaccinia virus protein C6. Proc Natl Acad Sci U S A PMID: 31127039
Kobori et al (2010) Butyrate stimulates IL-32α expression in human intestinal epithelial cell lines. Oncogene 16 2355 PMID: 20480520
Li et al (2018) Epigenetic control of IL-23 expression in keratinocytes is important for chronic skin inflammation. Nat Commun 9 1420 PMID: 29650963
Franklin et al (2014) Increased long-term potentiation at medial-perforant path-dentate granule cell synapses induced by selective inhibition of histone deacetylase 3 requires Fragile X mental retardation protein. Neurobiol Learn Mem 114 193 PMID: 24956240
Biernacka et al (2013) Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2. World J Gastroenterol 20 741 PMID: 23959956
Do you know of a great paper that uses Trichostatin A from Tocris? Please let us know.
Average Rating: 5 (Based on 1 Review.)
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.